GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation — successfully treated by extracorporeal photopheresis
In conclusion, CD19-directed CAR T-cell therapy seems to be feasible in patients after alloHCT but might comprise the potential risk of triggering GVHD, most likely depending on the T-cell source, donor compatibility, and the specific CAR construct used.
Authors
- Maria‐Luisa Schubert (ORCID: https://orcid.org/0009-0000-7853-4465)
- Michael Schmitt (ORCID: https://orcid.org/0000-0002-1579-1509)
- Uwe Haberkorn
- Carsten Müller‐Tidow (ORCID: https://orcid.org/0000-0002-7166-5232)
- Kiavasch Mohammad Nejad Farid
- Peter Dreger (ORCID: https://orcid.org/0000-0002-7429-8570)
- Gesine Bug (ORCID: https://orcid.org/0000-0003-2359-131X)
- Fabian Lang (ORCID: https://orcid.org/0000-0003-2890-029X)
- Anita Schmitt
Institutions
- Goethe University Frankfurt (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-18
- DOI
- https://doi.org/10.3389/fimmu.2024.1500177
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.41